<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793333</url>
  </required_header>
  <id_info>
    <org_study_id>142020</org_study_id>
    <nct_id>NCT05793333</nct_id>
  </id_info>
  <brief_title>Predictors of Node Positivity in Endometrial Cancer</brief_title>
  <official_title>Histological and Molecular Characteristics Predict the Risk of Nodal Involvement in Endometrial Cancer: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the role of histological and moleculr profile of endometrial cancer patietns&#xD;
      in predicting the risk of nodal metastases in endoemtrila cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>positive nodes</measure>
    <time_frame>12 months</time_frame>
    <description>positive nodes detected by sentinel node mappinig</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometrial Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patietns were submitted to standard treatment modality for managing endometrial cancer.&#xD;
        They will receive hsyterectomy (with or without bilateral salpingo-oophorectomy) plus&#xD;
        sentinel ndoe mapping.&#xD;
&#xD;
        After the procedures data regarding hystologcial charactersitcs of the tumor and molecular&#xD;
        features will be analyzed (as routine cliical practice).&#xD;
&#xD;
        We will correlate those data with findings achieved by sentinel nodes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histologically confirmed endometrila cancer&#xD;
&#xD;
          -  Data on molecular genomic profiling (POLE mutated, p53 abnormalities, MMRd/MSI-H, and&#xD;
             NSMP)&#xD;
&#xD;
          -  Data on histological characteristics of the ttumor&#xD;
&#xD;
          -  Execution of sentinel node mapping&#xD;
&#xD;
          -  Data on sentinel node status (negative vs. positive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage IVB endoemtrial cancer&#xD;
&#xD;
          -  consent withdraw&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 4, 2023</study_first_submitted>
  <study_first_submitted_qc>March 29, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 29, 2023</last_update_submitted>
  <last_update_submitted_qc>March 29, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Valentina Chiappa</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>sentinel node</keyword>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

